An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.

@article{Zhen2013AnHM,
  title={An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.},
  author={Yi Zhen and Audrey Thomas-Schoemann and Lilia Sakji and Pascaline Boudou-Rouquette and Nicolas Dupin and Laurent Mortier and Michel Vidal and François Goldwasser and Beno{\^i}t Blanchet},
  journal={Journal of chromatography. B, Analytical technologies in the biomedical and life sciences},
  year={2013},
  volume={928},
  pages={93-7}
}
Vemurafenib and erlotinib are two oral kinase inhibitors approved for the treatment of metastatic melanoma and advanced non-small cell lung cancer, respectively. In contrast with erlotinib, the single published method for analysis of vemurafenib in human plasma is based on mass spectrometry. The purpose of the present study was to develop an HPLC-UV method to simultaneously quantify these two drugs in plasma. Following liquid-liquid extraction, vemurafenib, erlotinib and sorafenib (internal… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…